Author: Steve Kopczak

• Is Sentinel Lymph Node Biopsy Necessary in Patients who Undergo Prophylactic Mastectomy?
• Madan V, Mamounas EP.
• Clin Breast Cancer. 2022 Dec 7:S1526-8209(22)00271-3. doi: 10.1016/j.clbc.2022.12.003. Epub ahead of print.

• Source abstract

• Patient-reported outcomes associated with reflex BRCA1/2 tumor and subsequent germline panel genetic testing for high-grade serous ovarian cancer.
• McCuaig JM, Stockley TL, Ferguson SE, Vicus D, Brennenstuhl S, Ott K, Kim RH, Metcalfe KA.
• J Genet Couns. 2022 Dec 7. doi: 10.1002/jgc4.1661. Epub ahead of print.

• Free Full Text

• Patient uptake of updated genetic testing following uninformative BRCA1 and BRCA2 results.
• Macklin-Mantia SK, Clift KE, Maimone S, Hodge DO, Riegert-Johnson D, Hines SL.
• J Genet Couns. 2022 Dec 7. doi: 10.1002/jgc4.1665. Epub ahead of print.

• Source abstract

• Detection of BRCA1, and BRCA2 in Matched Tumor Tissue and Circulating Cell-Free DNA in Patients with Prostate Cancer in a Real-World Setting.
• McFarland TR, Thomas VM, Nussenzveig R, Gebrael G, Sayegh N, Tripathi N, Sahu KK, Goel D, Maughan BL, Sirohi D, Agarwal N, Swami U.
• Biomedicines. 2022 Dec 7;10(12):3170. doi: 10.3390/biomedicines10123170.

• Free Full Text

• Does mainstream BRCA testing affect surgical decision-making in newly-diagnosed breast cancer patients?
• Ain Q, Richardson C, Mutebi M, George A, Kemp Z, Rusby JE.
• Breast. 2022 Dec 6:S0960-9776(22)00193-X. doi: 10.1016/j.breast.2022.12.001. Epub ahead of print.

• Free Full Text

• Pathologic Findings at Risk Reducing Surgery in BRCA and Non-BRCA Mutation Carriers: A Single-Center Experience.
• Cassani C, Rossi C, Camnasio CA, Urtis M, Fiandrino G, Grasso M, Zanellini F, Lucioni M, D’Ambrosio G, Di Toro A, Rossi M, Roccio M, Ferrari A, Secondino S, Nappi RE, Arbustini E, Paulli M, Spinillo A, Cesari S.
• Diagnostics (Basel). 2022 Dec 6;12(12):3054. doi: 10.3390/diagnostics12123054.

• Free Full Text

• A Single Variant in Pri-miRNA-155 Associated with Susceptibility to Hereditary Breast Cancer Promotes Aggressiveness in Breast Cancer Cells.
• Landeros N, Gonzalez-Hormazabal P, Pérez-Moreno P, Tapia JC, Jara L.
• Int J Mol Sci. 2022 Dec 6;23(23):15418. doi: 10.3390/ijms232315418.

• Free Full Text

• Non-parametric estimation of the age-at-onset distribution from a cross-sectional sample.
• Mandal S, Qin J, Pfeiffer RM.
• Biometrics. 2022 Dec 5. doi: 10.1111/biom.13804. Epub ahead of print.

• PMID: 36471903
• PubMed abstract
• Source abstract

• Tissue and liquid biopsy profiling reveal convergent tumor evolution and therapy evasion in breast cancer.
• Sivakumar S, Jin DX, Tukachinsky H, Murugesan K, McGregor K, Danziger N, Pavlick D, Gjoerup O, Ross JS, Harmon R, Chung J, Decker B, Dennis L, Frampton GM, Molinero L, Oesterreich S, Venstrom JM, Oxnard GR, Hegde PS, Sokol ES.
• Nat Commun. 2022 Dec 5;13(1):7495. doi: 10.1038/s41467-022-35245-x.

• PMID: 36470901
• PubMed abstract

• Free Full Text

• Targeting DNA damage response pathways in cancer.
• Groelly FJ, Fawkes M, Dagg RA, Blackford AN, Tarsounas M.
• Nat Rev Cancer. 2022 Dec 5. doi: 10.1038/s41568-022-00535-5. Epub ahead of print.

• PMID: 36471053
• PubMed abstract
• Source abstract

• Review

• CHEK2 Pathogenic Germline Variants in Patients With NSCLC.
• Sorscher S.
• JTO Clin Res Rep. 2022 Nov 19 [eCollection 2022 Dec];3(12):100439. doi: 10.1016/j.jtocrr.2022.100439.

• PMID: 36471681
• PubMed abstract

• Letter, Comment
• Free Full Text

Related:

•• Original research:

A High Percentage of NSCLC With Germline CHEK2 Mutation Harbors Actionable Driver Alterations: Survey of a Cancer Genomic Database and Review of Literature.

• PMID: 36061833
• PubMed abstract
• Free Full Text

• Does mainstream BRCA testing affect surgical decision-making in newly-diagnosed breast cancer patients?
• Ain Q, Richardson C, Mutebi M, George A, Kemp Z, Rusby JE.
• Breast. 2022 Dec 6:S0960-9776(22)00193-X. doi: 10.1016/j.breast.2022.12.001. Epub ahead of print.

• Free Full Text

• Pathologic Findings at Risk Reducing Surgery in BRCA and Non-BRCA Mutation Carriers: A Single-Center Experience.
• Cassani C, Rossi C, Camnasio CA, Urtis M, Fiandrino G, Grasso M, Zanellini F, Lucioni M, D’Ambrosio G, Di Toro A, Rossi M, Roccio M, Ferrari A, Secondino S, Nappi RE, Arbustini E, Paulli M, Spinillo A, Cesari S.
• Diagnostics (Basel). 2022 Dec 6;12(12):3054. doi: 10.3390/diagnostics12123054.

• Free Full Text

• A Single Variant in Pri-miRNA-155 Associated with Susceptibility to Hereditary Breast Cancer Promotes Aggressiveness in Breast Cancer Cells.
• Landeros N, Gonzalez-Hormazabal P, Pérez-Moreno P, Tapia JC, Jara L.
• Int J Mol Sci. 2022 Dec 6;23(23):15418. doi: 10.3390/ijms232315418.

• Free Full Text

• Non-parametric estimation of the age-at-onset distribution from a cross-sectional sample.
• Mandal S, Qin J, Pfeiffer RM.
• Biometrics. 2022 Dec 5. doi: 10.1111/biom.13804. Epub ahead of print.

• PMID: 36471903
• PubMed abstract
• Source abstract

• Tissue and liquid biopsy profiling reveal convergent tumor evolution and therapy evasion in breast cancer.
• Sivakumar S, Jin DX, Tukachinsky H, Murugesan K, McGregor K, Danziger N, Pavlick D, Gjoerup O, Ross JS, Harmon R, Chung J, Decker B, Dennis L, Frampton GM, Molinero L, Oesterreich S, Venstrom JM, Oxnard GR, Hegde PS, Sokol ES.
• Nat Commun. 2022 Dec 5;13(1):7495. doi: 10.1038/s41467-022-35245-x.

• PMID: 36470901
• PubMed abstract

• Free Full Text

• Targeting DNA damage response pathways in cancer.
• Groelly FJ, Fawkes M, Dagg RA, Blackford AN, Tarsounas M.
• Nat Rev Cancer. 2022 Dec 5. doi: 10.1038/s41568-022-00535-5. Epub ahead of print.

• PMID: 36471053
• PubMed abstract
• Source abstract

• Review

• CHEK2 Pathogenic Germline Variants in Patients With NSCLC.
• Sorscher S.
• JTO Clin Res Rep. 2022 Nov 19 [eCollection 2022 Dec];3(12):100439. doi: 10.1016/j.jtocrr.2022.100439.

• PMID: 36471681
• PubMed abstract

• Letter, Comment
• Free Full Text

Related:

•• Original research:

A High Percentage of NSCLC With Germline CHEK2 Mutation Harbors Actionable Driver Alterations: Survey of a Cancer Genomic Database and Review of Literature.

• PMID: 36061833
• PubMed abstract
• Free Full Text

• Insurance Coverage of Prophylactic Mastectomies: A National Review of the United States.
• Ha M, Ngaage LM, Finkelstein ER, Klein M, Yang A, Colohan SM, Nurudeen SM, Terhune JH, Slezak S, Rasko YM.
• Clin Breast Cancer. 2022 Dec 5:S1526-8209(22)00269-5. doi: 10.1016/j.clbc.2022.12.001. Epub ahead of print.

• Source abstract

• Hereditary breast cancer: syndromes, tumour pathology and molecular testing.
• Sokolova A, Johnstone KJ, McCart Reed AE, Simpson PT, Lakhani SR.
• Histopathology. 2022 Dec 5. doi: 10.1111/his.14808. Epub ahead of print.

• PMID: 36468211
• PubMed abstract
• Source abstract

• Review
• Free Full Text

• The CHK2 kinase is recurrently mutated and functionally impaired in the germline of pediatric cancer patients.
• Wagener R, Walter C, Auer F, Alzoubi D, Hauer J, Fischer U, Varghese J, Dugas M, Borkhardt A, Brozou T.
• Int J Cancer. 2022 Dec 5. doi: 10.1002/ijc.34390. Epub ahead of print.

• PMID: 36468172
• PubMed abstract
• Source abstract

• Yes, We Can, But Should We? Ethical Considerations in Reporting Germline Findings From Paired Tumor-Normal Genomic Testing in Patients With Advanced Cancer.
• Hunter CL, Helft PR.
• J Clin Oncol. 2022 Dec 5:JCO2200796. doi: 10.1200/JCO.22.00796. Epub ahead of print.

• PMID: 36469841
• PubMed abstract
• Source abstract

• Commentary
• Free Full Text